Actively Recruiting

Age: 60Years +
All Genders
NCT05908812

Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity

Led by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Updated on 2024-08-01

120

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational study is to compare glycemic control and irisin levels in subjects with diabetes mellitus type 2 with sarcopenic obesity vs non-sarcopenic obesity. The main questions it aims to answer are: Is glycemic control worse in diabetic patients with sarcopenic obesity? Are irisin levels higher in patients with non-sarcopenic obesity? Participants will be asked to: * Fill in three questionaries on lifestyle * Perform two physical performance tests The investigators will collect the following data: * Anthropometric measurements * Body composition by bioelectrical impedance analysis. * Results of routine blood analyses * Irisin levels by drawing a vial of blood from the antecubital vein

CONDITIONS

Official Title

Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity

Who Can Participate

Age: 60Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diabetes mellitus type 2 diagnosed less than 10 years before
  • Age over 60 years
  • Body Mass Index (BMI) over 30 kg/m2
  • Estimated Glomerular Filtration Rate (eGFR) above 30 ml/min
  • On stable antidiabetic therapy for at least 3 months
Not Eligible

You will not qualify if you...

  • Use of insulin or insulin secretagogues
  • Diagnosis of type 1 diabetes or history of diabetic ketoacidosis
  • Neuromuscular diseases
  • Endocrine disorders causing muscle disease (e.g., hypercortisolism, growth hormone deficiency, acromegaly, adrenal insufficiency, hypopituitarism, male hypogonadism, hyperparathyroidism, hypoparathyroidism)
  • Severe vitamin D deficiency (less than 12 ng/ml)
  • Blood disorders (hemoglobinopathies)
  • Prolonged immobilization
  • Conditions causing fluid retention (severe heart failure NYHA class III/IV, severe kidney or liver failure)
  • Active cancers within the past 5 years
  • Severe arthritis of the knee or hip
  • Having a pacemaker

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Policlinico di Bari

Bari, Italy, 70124

Actively Recruiting

Loading map...

Research Team

F

Francesco Giorgino, MD, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here